Delgocitinib is a JAK inhibitor that blocks the activation of the JAK-STAT pathway which has been shown to play a key role in the pathophysiology of chronic inflammatory skin diseases.

When it comes to your baby’s delicate skin, especially on their face, finding the right moisturiser isn’t just a nice-to-have, it’s a must. Baby skin is thinner and more sensitive than adult skin, ...

The U.S. Food and Drug Administration (FDA) has signed off on the first-ever cream specifically approved for treating chronic ...

Adult patients with moderate to severe hand eczema with previous treatment failure or in whom topical corticosteroids are ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Becoming the first approved treatment for chronic hand eczema in the U.S., Leo Pharma A/S’s Anzupgo (delgocitinib) received ...

The first therapy specifically indicated for chronic hand eczema (CHE) has passed muster at the FDA.

Danish dermatology specialist Leo Pharma has scored an FDA approval that makes its JAK inhibitor cream Anzupgo (del | Despite chronic hand eczema affecting 1 in 10 people worldwide, there was no ...

The FDA has approved a new treatment, sold under the name Anzupgo and containing a drug called delgocitinib, as the first skin cream for adults with long-term or chronic hand eczema (CHE), which ...

The topical JAK inhibitor is the first treatment approved specifically for adults with moderate-to-severe chronic hand eczema.

Promising review: "Incredible product! All you have to do is take the ice cream out of the freezer, and you no longer have to ...